DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ct7vgz/pcsk9_and_other) has announced the addition of the "PCSK9 and Other Novel Hypercholesterolemia Drugs" report to their offering.
The PCSK9 and Other Novel Hypercholesterolemia Drugs, 2014 - 2024' report provides an extensive study of the new class of prescription drugs being evaluated for the treatment of high cholesterol levels caused both by genetic and lifestyle factors.
The possibility of a drug to become blockbuster depends on various factors. In addition to safety and efficacy, other factors include cost, mode of administration, side effects and their approval and availability in various geographies. For each of these new classes of drugs, we have highlighted the key drivers and limiting factors. We have also presented our own perspective on how the acceptance and evolution of these drugs is likely to advance in the coming years. The analysis is backed by an extensive review of the hypercholesterolemia / dyslipidemia landscape and familial hypercholesterolemia (HoFH and HeFH) markets.
The base year for the report is 2013. The report provides market forecasts for the following two time horizons: 2014 - 2019 (short-midterm) and 2019 - 2024 (long term), respectively. The figures mentioned in this report are in USD, unless otherwise specified.
- With statins going off-patent, pharmaceutical companies are hunting for next blockbusters for hypercholesterolemia. The approval and launch of Kynamro (ISIS Pharmaceuticals / Genzyme) and Juxtapid (Aegerion Pharmaceuticals) in late 2012 / early 2013 has changed the treatment paradigm for homozygous familial hypercholesterolemia.
- The market for developing novel cholesterol lowering drugs has gained attention of a number of multinational pharmaceutical companies including Amgen, Sanofi, Pfizer, GSK, Eli Lilly, Roche, Johnson & Johnson and more. Overall, there are 27 companies developing 29 molecules in clinical trials.
- Evolocumab, being developed by Amgen, has been filed with the FDA and EMA for approval. Four more drugs are being evaluated in Phase III clinical trials. Three of these five late stage drugs are PCSK9 inhibitors (monoclonal antibodies), all of which are being developed by large multinational pharmaceutical companies.
- All three late stage PCSK9 inhibitors are monoclonal antibodies. Other approaches being investigated by drug developers include the use of antisense / siRNA and synthetic molecules.
- 2015 is likely to witness parallel launch of two anti-PCSK9 mAbs. We expect Evolocumab and Alirocumab to be made commercially available during 2015, while Bococizumab is expected to be available by 2017.
- Anacetrapib, an oral CETP inhibitor from Merck, can give head to head competition to PCSK9 inhibitors in dyslipidemia / hypercholesterolemia market if the Phase III outcome trial REVEAL shows positive results.
- In the base scenario, we forecast the market to hit USD 10 billion + sales by 2020. The upside is likely to be higher as the same drugs also start getting evaluated for treatment in the non-US and non-EU5 regions.
Key Topics Covered:
2. Executive Summary
3. Hypercholesterolemia: A Major Problem
4. Current Market Landscape
5. Novel Marketed Drugs: Mttp Inhibitors And Apo B Gene Silencer
6. Pcsk9 Inhibitors: Key Molecules And Future Outlook
7. Cetp Inhibitors: Key Molecules And Future Outlook
8. Overall Market Outlook
10. Appendix 1: Tabulated Data
11. Appendix 2: List Of Companies
For more information visit http://www.researchandmarkets.com/research/ct7vgz/pcsk9_and_other